Scynexis SCYX
NASDAQ SCYX
$4.91 -0.24 (-4.66%)
At close: Sep 9, 2026 · 4:00 PM EDT

Scynexis (SCYX) Cash from Investing Activities (2013 - 2026)

Scynexis' (SCYX) quarterly Cash from Investing Activities came in at -$24.8 million in Q2 2026, down 319.62% on a YoY basis from $11.3 million in Q2 2025, and down 4615.81% quarter-over-quarter from -$525000.0 in Q1 2026.

Analysis

Scynexis (SCYX) Cash from Investing Activities (2013 - 2026) Analysis & Trends

Scynexis (SCYX) has reported Cash from Investing Activities for 14 consecutive years, with -$24.8 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Cash from Investing Activities fell 319.62% year-over-year to -$24.8 million; the trailing twelve-month figure through Jun 2026 stood at -$24.7 million (down 207.18% YoY), and the FY2025 full-year result was $24.3 million, up 295.22% from the prior year.
  • Cash from Investing Activities retreated to -$24.8 million in Q2 2026 per SCYX's latest filing, from -$525000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $12.4 million in Q1 2025 and bottomed at -$27.4 million in Q3 2022.
  • Historically, Cash from Investing Activities has averaged -$3.8 million across 5 years, with a median of -$525000.0 in 2026.
  • The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities tumbled 8000.59% in 2022, then soared 721.65% in 2025.
  • Over 5 years, Cash from Investing Activities stood at -$27.4 million in 2022, then jumped by 92.14% to -$2.2 million in 2023, then fell by 21.61% to -$2.6 million in 2024, then sank by 351.82% to -$11.8 million in 2025, then sank by 109.39% to -$24.8 million in 2026.
  • According to Business Quant data, Cash from Investing Activities over the past three periods registered -$24.8 million, -$525000.0, and -$11.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn -569.00 Mn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn -10.35 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn -45.80 Mn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn -92.70 Mn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn -
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn 329.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn -363.46 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn -3.84 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn 281.26 Mn
10 Scynexis 58.41 Mn -56.29 Mn - -24.76 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -24.76 Mn
Mar 31, 2026 -525,000.00
Dec 31, 2025 -11.82 Mn
Sep 30, 2025 12.42 Mn
Jun 30, 2025 11.27 Mn
Mar 31, 2025 12.44 Mn
Dec 31, 2024 -2.62 Mn
Sep 30, 2024 1.94 Mn
Jun 30, 2024 1.37 Mn
Mar 31, 2024 5.45 Mn
Dec 31, 2023 -2.15 Mn
Sep 30, 2023 -26.34 Mn
Jun 30, 2023 -6.38 Mn
Sep 30, 2022 -27.38 Mn
Mar 31, 2022 -9,000.00
Dec 31, 2021 -583,000.00
Sep 30, 2021 -338,000.00
Jun 30, 2021 -51,000.00
Mar 31, 2021 -200,000.00
Sep 30, 2020 3.57 Mn